Spyre Therapeutics, Inc. — Director's Dealing 2017

Dec 6, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aeglea BioTherapeutics, Inc. (AGLE)
CIK: 0001636282
Period of Report: 2017-12-01

Reporting Person: GEORGIOU GEORGE (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-01	Director Stock Option (right to buy)	$4.73	A	30000	Acquired	2027-11-30	Common Stock (30000)	Direct

Footnotes

F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on January 1, 2018 until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.